BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 174 produtos para "BTK".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Fórmula:C25H23ClN4O4Pureza:98.68% - 99.63%Cor e Forma:SolidPeso molecular:478.928AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Fórmula:C33H31FN6O3Pureza:≥95%Cor e Forma:SolidPeso molecular:578.64IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Fórmula:C22H22N6OPureza:99.88% - 99.88%Cor e Forma:Yellow SolidPeso molecular:386.45Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Fórmula:C25H23ClN6O3Pureza:99.27% - 99.95%Cor e Forma:White SolidPeso molecular:490.942MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Fórmula:C41H41N9O8Pureza:95.93% - 97.60%Cor e Forma:SolidPeso molecular:787.82Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Cor e Forma:White SolidPeso molecular:665.7597Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Fórmula:C24H25N5O3Pureza:99.94%Cor e Forma:SolidPeso molecular:431.487Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Fórmula:C26H23N7O2Pureza:99.20%Cor e Forma:SolidPeso molecular:465.5065Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C26H25N3O3Pureza:97.77% - 99.54%Cor e Forma:SolidPeso molecular:427.495DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Cor e Forma:SolidPeso molecular:991.163DFCI-002-06
CAS:DFCI-002-06 is an orally active dual-targeted HCK/BTK PROTAC degrader, demonstrating DC₅₀ values of 1.3 nM for HCK and 4.5 nM for BTK. It retains superior antitumor activity compared to dual-targeted HCK/BTK inhibitors and induces apoptosis in cancer cells. DFCI-002-06 is applicable in studies of MYD88-mutant B-cell malignancies.Fórmula:C44H46N10O5Peso molecular:794.92BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Cor e Forma:SolidPeso molecular:483.93TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Cor e Forma:Odour SolidFDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Cor e Forma:Odour SolidPROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Cor e Forma:SolidPeso molecular:976.97PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Fórmula:C43H43N9O4Cor e Forma:SolidPeso molecular:749.86BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Fórmula:C23H32N4O5Cor e Forma:SolidPeso molecular:444.532LFM-A13
CAS:LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Fórmula:C11H8Br2N2O2Pureza:99.50%Cor e Forma:White SolidPeso molecular:360Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Fórmula:C50H48N12O4Pureza:98%Cor e Forma:SolidPeso molecular:880.99FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Cor e Forma:Liquid
